The presence or absence of standard modifiable cardiovascular risk factors in patients with myocardial infarction impacts long-term but not 30-day mortality: a UK Biobank prospective cohort study
In this population-based cohort, SMuRF status significantly impacted long-term but not short-term mortality following MI, indicating early survival is predominantly driven by acute-phase factors rather than baseline cardiovascular risk profiles.
Authors
- Derek P. Chew (ORCID: https://orcid.org/0000-0003-3593-296X)
- Karlheinz Peter (ORCID: https://orcid.org/0000-0002-8040-2258)
- Wen Kai Wong (ORCID: https://orcid.org/0000-0003-1712-0984)
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- Fumihiko Takeuchi (ORCID: https://orcid.org/0000-0003-3185-5661)
- Li Lian Kuan (ORCID: https://orcid.org/0000-0003-1669-4564)
Institutions
- Baker Heart and Diabetes Institute (AU)
- The University of Melbourne (AU)
- Monash Health (AU)
- Melbourne Health (AU)
- Imperial College London (GB)
- Monash University (AU)
- Blackburn College (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1093/eurjpc/zwaf274
- Citations
- 3
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Amgen
- Pfizer
- Merck KGaA
- Anthera
- Kowa Company
- InfraRedx
- Boehringer Ingelheim España
- Novo Nordisk
- AstraZeneca Pharma Poland
- Fonds de dotation CSL Behring pour la recherche
- Esperion Therapeutics
- Takeda Canada
- Daiichi Sankyo Europe